2026-09-21T12:50:34Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/422082022-01-13T07:53:45Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Teo Forcht Dagi and Pedro Huertas.
Khan, Rehan A. (Rehan Abbas)
Harvard University--MIT Division of Health Sciences and Technology.
Harvard University--MIT Division of Health Sciences and Technology
2008-09-03T14:53:47Z
2008-09-03T14:53:47Z
2007
2007
http://hdl.handle.net/1721.1/42208
230824588
Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2007.
Includes bibliographical references (leaves 71-73).
The leading publicly traded pharmaceutical companies ("Big Pharma) in the US are facing a commercial crisis - their sales structure collectively consisting of more than 100,000 pharmaceutical sales representatives, originally setup to launch blockbusters, is suffering as a result of shrinking pipelines and low NME approvals. Although sales and marketing constitutes by far the largest corporate expense at 33% of revenues, sales productivity continues to decline. The goal of this study is to explore how pharmaceutical sales will change over the next 5 - 7 years and more specifically explore the role technology (including the internet) will play in the sales process. The study focuses on testing the perceptions of two key stakeholders -pharmaceutical executives and current medical students (future physicians) regarding the future of pharmaceutical sales process. Accordingly, 33 individuals were interviewed of which 18 were pharmaceutical executives and 15 were future physicians. The study tests three hypotheses: 1. Pharma executives believe that sales representative based detailing will continue to be the predominant method to engage and sell to physician customers while future physicians believe that technology will play a dominant role in the pharmaceutical detailing process. 2. Pharmaceutical executives agree that the most effective and ethical method to convey the benefits and challenges of an ethical pharmaceutical product are via a trained sales representative while future physicians believe that the sales representative does not effectively and ethically convey the merits of the relevant pharmaceutical therapy. 3. Person to person contact is not essential in conveying the merits of a particular ethical therapy - pharmaceutical executives disagree with this premise while future physicians agree.
(cont.) The data sets were compared using the following statistical tests: Yates' chi-square test, Armitage's chi-squared test and Two sample test of binomial proportions. In conclusion, the data showed that the perceptions of pharma executives and future physicians were in concurrence with each other.
by Rehan A. Khan.
S.M.
73 leaves
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by
copyright. They may be viewed from this source for any purpose, but
reproduction or distribution in any format is prohibited without written
permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
Harvard University--MIT Division of Health Sciences and Technology.
What future physicians want : a comparative analysis of the perception of medical students and pharmaceutical industry executives regarding the future of pharmaceutical sales
Comparative analysis of the perception of medical students and pharmaceutical industry executives regarding the future of pharmaceutical sales
Thesis
application/pdf
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="980ec0d2-f023-4005-aba6-c594105507ee">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>What future physicians want : a comparative analysis of the perception of medical students and pharmaceutical industry executives regarding the future of pharmaceutical sales</Title>
<Subtitle>Comparative analysis of the perception of medical students and pharmaceutical industry executives regarding the future of pharmaceutical sales</Subtitle>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2007</PublicationDate>
<Authors>
<Author>
<DisplayName>Khan, Rehan A. (Rehan Abbas)</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Harvard University--MIT Division of Health Sciences and Technology.</Keyword>
<Abstract>The leading publicly traded pharmaceutical companies ("Big Pharma) in the US are facing a commercial crisis - their sales structure collectively consisting of more than 100,000 pharmaceutical sales representatives, originally setup to launch blockbusters, is suffering as a result of shrinking pipelines and low NME approvals. Although sales and marketing constitutes by far the largest corporate expense at 33% of revenues, sales productivity continues to decline. The goal of this study is to explore how pharmaceutical sales will change over the next 5 - 7 years and more specifically explore the role technology (including the internet) will play in the sales process. The study focuses on testing the perceptions of two key stakeholders -pharmaceutical executives and current medical students (future physicians) regarding the future of pharmaceutical sales process. Accordingly, 33 individuals were interviewed of which 18 were pharmaceutical executives and 15 were future physicians. The study tests three hypotheses: 1. Pharma executives believe that sales representative based detailing will continue to be the predominant method to engage and sell to physician customers while future physicians believe that technology will play a dominant role in the pharmaceutical detailing process. 2. Pharmaceutical executives agree that the most effective and ethical method to convey the benefits and challenges of an ethical pharmaceutical product are via a trained sales representative while future physicians believe that the sales representative does not effectively and ethically convey the merits of the relevant pharmaceutical therapy. 3. Person to person contact is not essential in conveying the merits of a particular ethical therapy - pharmaceutical executives disagree with this premise while future physicians agree.</Abstract>
<Abstract>(cont.) The data sets were compared using the following statistical tests: Yates' chi-square test, Armitage's chi-squared test and Two sample test of binomial proportions. In conclusion, the data showed that the perceptions of pharma executives and future physicians were in concurrence with each other.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>